RetinaCME
EXPERT INTERVIEWCMEABO MOC

Targeting Angiopoietin-2 in Retinal and Choroidal Vascular Diseases: A New Approach to Treatment

Author(s)/Faculty: David Eichenbaum, MD; Rishi P. Singh, MD
Release Date: 12/2/2021Expiration Date: 12/1/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 0.75
Content Type: LectureProvider:
The management of retinal and choroidal vascular diseases with intravitreal anti-vascular endothelial growth factor (VEGF) therapies has resulted in significant visual and anatomic improvements for most patients, yet there are still a proportion of patients who receive little or suboptimal responses to anti-VEGF therapy. The identification of alternative pathways involved in increased vascular permeability and abnormal angiogenesis are attractive targets to address this unmet need. The angiopoietin/Tie2 pathway is one such promising target that is being investigated in clinical studies for disease management. In this CME activity, experts in the field review the role of angiopoietins in the regulation of vascular stability as well as evaluate emerging injectable therapies that act on the Tie2 pathway for the management of retinal and choroidal vascular diseases.